Searchable abstracts of presentations at key conferences in endocrinology

ea0037gh1 | The Geoffrey Harris Prize Lecture | ECE2015

Understanding energy sensors, understanding neuroendocrine function

Dieguez Carlos

The question on how cells, tissues and organisms are able to detect energy/nutrient availability has been the focus of research for many years. Data gleaned recently have identified different nutrient-sensing circuits implicated in the regulation of different homeostatic process. Furthermore, there has been a steady increase in our knowledge regarding the cellular and molecular mechanisms involved in nutrient detection and integration. In particular, this has allowed for a bet...

ea0037gh1biog | The Geoffrey Harris Prize Lecture | ECE2015

Geoffrey Harris Prize Winner UK

Dieguez Carlos

This prestigious prize is intended for established workers in the field of basic and clinical neuroendocrinology and is generously supported by Ipsen. This year’s recipient is Prof. Carlos Dieguez. The prize will be presented as part of the ECE 2015 opening ceremony where Prof. Dieguez will deliver his lecture. Prof. Dieguez will also deliver two other lectures at future ESE scientific meetings. Further information can be found at <a href="http://www.ese-hormones.org/priz...

ea0081d3.2 | Adjuvant Radioactive Iodine Therapy for low to intermediate risk differentiated thyroid cancer patients | ECE2022

For: Adjuvant radioactive iodine therapy for low to intermediate risk differentiated thyroid cancer patients

Galofre Juan Carlos

Current indications for adjuvant Radioactive Iodine (RAI) in low- and intermediate-risk differentiated thyroid cancer (DTC) are controversial. At the same time, there is universal consensus for personalized DTC management according to individual patient needs, as there does not appear to be a ‘‘right’’ way to treat patients with DTC. According to the Martinique Principles 1, adjuvant RAI treatment has many goals, including: initial stagi...

ea0063s20.1 | News on nutrition: when to eat what | ECE2019

Precision nutrition for managing obesity – does it work?

Celis-Morales Carlos

Background: The epidemic of obesity, together with its associated health burden, continues to spread globally. It is estimated that approximately 2.1 billion adults worldwide are now classified as overweight or obese. Thus, there is an urgent need to develop more effective strategies for preventing and managing obesity. Most population strategies to reduce the rising prevalence of non-communicable diseases (NCDs) have used a ‘one size fits all’ public health recommen...

ea0070ep79 | Bone and Calcium | ECE2020

Hypocalcemia due to pseudohypoparathyroidism diagnosed in adulthood

Antich Barceló Carlos

Introduction: Pseudohypoparathyroidism (PHP) refers to a heterogeneous group of rare metabolic diseases, all characterized by end-organ resistance to the action of different hormones, primarily PTH. Main clinical characteristics are hypocalcemia and hyperphosphoremia associated with elevated parathyroid hormone (PTH) levels, frequently encompassing additional heterogeneous features, known as Albright’s hereditary osteodystrophy. A molecular cause can be identified in 80&...

ea0056ss1.3 | Special Symposium: Bone &amp; Vitamin D (Endorsed by Endocrine Connections) | ECE2018

The effects of Vitamin D deficiency on macrophages function, cholesterol metabolism and cardiometabolic disease

Bernal-Mizrachi Carlos

Vitamin D has been shown not only to be important for bone and calcium metabolism but also for homeostasis of critical tissues involved in vascular disease. The vitamin D receptor (VDR) and the 1a-hydroxylase enzyme are present in critical cells implicated in the development of vascular disease. Vitamin D influences multiple mechanisms to decrease vascular inflammation: it suppresses the renin-angiotensin system, promotes endothelial nitric oxide release, decreases vascular in...

ea0081p228 | Thyroid | ECE2022

When patients with DTC can be discharged to primary care

Amich Nicolas , Chumbiauca Estefania , Carlos Galofre Juan

Purpose: To evaluate if patients with low- or intermediate-risk differentiated thyroid cancer (DTC) can be discharged to primary care.Material and Methods: The clinical records and evolution of 346 patients with DTC who had undergone surgery between 1995 and 2020 with a follow-up after a mean of 7.6 ± 6.1 years were retrospectively reviewed. All had a low or intermediate risk of recurrence as defined under the 2015 ATA risk stratification system and...

ea0041gp63 | Clinical Case Reports | ECE2016

Triple X and premature ovarian insufficiency – case report

Roque Catarina , Moniz Catarina , Vasconcelos Carlos

Introduction: Premature ovarian insufficiency is characterized by precocious depletion of ovarian follicles, associated with amenorrhea, hypoestrogenism and high gonadotropin levels. It afflicts 1% of the female population and in 5% cases it is due to X chromosome abnormalities.Case report: A 22 year old previously healthy female, presented to the Endocrinology Clinic due to amenorrhea. She had no family history of amenorrhea, her menarche was at age 11 ...

ea0041ep120 | Bone &amp; Osteoporosis | ECE2016

Hypophosphatasia: a novel mutation

Lopez Gallardo Gema , Roa Llamazares Carlos

Introduction: Hypophosphatasia (HPP) is a rare genetic disease of very variable severity (from letal to mild). HPP results from APL gene mutations, which lead to a deficiency of tissue-nonspecifc alcaline phosphatase (TNAP), and accumulation of inorganic pyrophosphate, a potent inhibitor of mineralization that is also a natural substrate of TNAP in the extracelular space. HPP causes mineralization disorders including soft bones (rickets, osteomalacia, fractures) and defects in...

ea0037ep750 | Pituitary: clinical | ECE2015

Rate of Prolactin suppression can predict future prolactin normalisation, tumour shrinkage and time to remission in male macroprolactinomas

Tirosh Amit , Benbassat Carlos , Shimon Ilan

Introduction: Dopamine agonists are the mainstay treatment for prolactinomas, but clinical characteristics that predict their effects on prolactin (PRL) suppression and tumour shrinkage are missing. Our study aimed to find measures in early follow-up of men harbouring macroprolactinomas, that will predict dynamics of PRL decrease and adenoma shrinkage.Methods: A single centre historical prospective study, including a consecutive group of 71 men with pitu...